Northwest Biotherapeutics makes changes to management team

Linda Powers becomes chief executive

US biotechnology firm Northwest Biotherapeutics (NWBT) has made changes to and expanded its management team.

Linda Powers, who has been chairman since May 2007, has become chief executive, while Dr Anthony Maida, a senior executive in the field of cancer immune therapies, is joining the company as chief operating officer on 20 June.

Dr Alton Boynton, the scientific founder of NWBT and chief executive since May 2007, is returning to the position of chief scientific officer.

Les Goldman, a former partner at US law firm Skadden, Arps, specialising in advanced technology commercialisation, has been appointed as senior vice president, business development. Dr Marnix Bosch will continue in his role as chief technology officer.

You may also like

Pharmaceutical

AIRPLAN S.A. showcases its dual strength in engineering and technology at CPHI 2025

AIRPLAN S.A. will once again participate in CPHI 2025, the world’s premier pharmaceutical event, taking place from October 28 to 30 in Frankfurt (Hall 9.0, booth B29)
Pharmaceutical

NEXTEN: Tomorrow's Tableting Innovations

A world première of the new IMA Active tablet presses
Pharmaceutical

Global vaccine patents up 7% in a year despite US government's stance

Vaccine patent applications show sustained momentum after the COVID pandemic, with RNA vaccines now dominating the filings
Manufacturing

Rezon Bio launches as European biologics CDMO with mirrored sites in Poland

New CDMO combines cost efficiency, digital innovation and EMA/FDA-audited facilities in Gdańsk and Warsaw to accelerate biologics development and commercialisation
Manufacturing

Baxter earns first Gold Resiliency Badge from HIRC across IV, nutrition and premix drug categories

The company is the first manufacturer to receive the Healthcare Industry Resilience Collaborative’s gold badge for IV solutions, nutrition solutions and premix drugs, recognising its leadership in building a transparent, reliable and disruption-ready healthcare supply chain
You need to be a subscriber to read this article.
Click here to find out more.
Analysis

From West to East: building biotech bridges across APAC and the Middle East

Amid rising geopolitical uncertainty, US biotech companies are looking beyond tariffs and trade tensions to expand into Asia-Pacific and the Middle East
Distribution

Er-Kim partners with Sentynl Therapeutics to expand access to ultra-rare disease treatments Nulibry and Zokinvy

The collaboration aims to provide timely access to these EMA- and FDA-approved therapies for patients with life-threatening ultra-rare conditions, including molybdenum cofactor deficiency Type A and Hutchinson-Gilford Progeria Syndrome
Subscribe now